Literature DB >> 10103187

LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability.

L J Green1, P Marder, L L Mann, L C Chio, W L Current.   

Abstract

LY303366 is a semisynthetic analog of the antifungal lipopeptide echinocandin B that inhibits (1,3)-beta-D-glucan synthase and exhibits efficacy in animal models of human fungal infections. In this study, we utilized flow cytometric analysis of propidium iodide uptake, single-cell sorting, and standard microbiological plating methods to study the antifungal effect of LY303366 on Saccharomyces cerevisiae and Candida albicans. Our data indicate that an initial 5-min pulse treatment with LY303366 caused yeasts to take up propidium iodide and lose their ability to grow. Amphotericin B and cilofungin required longer exposure periods (30 and 180 min, respectively) and higher concentrations to elicit these fungicidal effects. These two measurements of fungicidal activity by LY303366 were highly correlated (r > 0.99) in concentration response and time course experiments. As further validation, LY303366-treated yeasts that stained with propidium iodide were unable to grow in single-cell-sorted cultures. Our data indicate that LY303366 is potent and rapidly fungicidal for actively growing yeasts. The potency and rapid action of this new fungicidal compound suggest that LY303366 may be useful for antifungal therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10103187      PMCID: PMC89213     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analyses.

Authors:  H M Davey; D B Kell
Journal:  Microbiol Rev       Date:  1996-12

2.  In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.

Authors:  O Uzun; S Kocagöz; Y Cetinkaya; S Arikan; S Unal
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic.

Authors:  R S Gordee; D J Zeckner; L C Howard; W E Alborn; M Debono
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

4.  In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.

Authors:  M A Pfaller; S A Messer; S Coffman
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

5.  Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo.

Authors:  M S Bartlett; W L Current; M P Goheen; C J Boylan; C H Lee; M M Shaw; S F Queener; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

6.  Resistance of clinically important yeasts to antifungal agents.

Authors:  F C Odds
Journal:  Int J Antimicrob Agents       Date:  1996-02       Impact factor: 5.283

Review 7.  Antibiotics that inhibit fungal cell wall development.

Authors:  M Debono; R S Gordee
Journal:  Annu Rev Microbiol       Date:  1994       Impact factor: 15.500

8.  Amphotericin B susceptibility of Candida species assessed by rapid flow cytometric membrane potential assay.

Authors:  J V Ordóñez; N M Wehman
Journal:  Cytometry       Date:  1995-06-15

9.  Characterization and cilofungin inhibition of solubilized Aspergillus fumigatus (1,3)-beta-D-glucan synthase.

Authors:  D Beaulieu; J Tang; S B Yan; J M Vessels; J A Radding; T R Parr
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

10.  Cilofungin (LY121019) inhibits Candida albicans (1-3)-beta-D-glucan synthase activity.

Authors:  C S Taft; T Stark; C P Selitrennikoff
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

View more
  11 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 2.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

3.  Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.

Authors:  A H Groll; D Mickiene; R Petraitiene; V Petraitis; C A Lyman; J S Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

4.  Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.

Authors:  A H Groll; D Mickiene; V Petraitis; R Petraitiene; K H Ibrahim; S C Piscitelli; I Bekersky; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  Combination of two activating mutations in one HOG1 gene forms hyperactive enzymes that induce growth arrest.

Authors:  Gilad Yaakov; Michal Bell; Stefan Hohmann; David Engelberg
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

6.  Anidulafungin.

Authors:  David Murdoch; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis.

Authors:  Luciano Polonelli; Walter Magliani; Stefania Conti; Luisa Bracci; Luisa Lozzi; Paolo Neri; Daniela Adriani; Flavia De Bernardis; Antonio Cassone
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

8.  Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening.

Authors:  Andrea Sussman; Karen Huss; Li-Chun Chio; Steve Heidler; Margaret Shaw; Doreen Ma; Guoxin Zhu; Robert M Campbell; Tae-Sik Park; Palaniappan Kulanthaivel; John E Scott; John W Carpenter; Mark A Strege; Matthew D Belvo; James R Swartling; Anthony Fischl; Wu-Kuang Yeh; Chuan Shih; Xiang S Ye
Journal:  Eukaryot Cell       Date:  2004-08

Review 9.  Methods for in vitro evaluating antimicrobial activity: A review.

Authors:  Mounyr Balouiri; Moulay Sadiki; Saad Koraichi Ibnsouda
Journal:  J Pharm Anal       Date:  2015-12-02

10.  Amiodarone induces cell wall channel formation in yeast Hansenula polymorpha.

Authors:  Tatyana S Kalebina; Sviatoslav S Sokolov; Irina O Selyakh; Darya P Vanichkina; Fedor F Severin
Journal:  Springerplus       Date:  2015-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.